HRP20201815T1 - Nukleinske kiseline za liječenje alergija - Google Patents

Nukleinske kiseline za liječenje alergija Download PDF

Info

Publication number
HRP20201815T1
HRP20201815T1 HRP20201815TT HRP20201815T HRP20201815T1 HR P20201815 T1 HRP20201815 T1 HR P20201815T1 HR P20201815T T HRP20201815T T HR P20201815TT HR P20201815 T HRP20201815 T HR P20201815T HR P20201815 T1 HRP20201815 T1 HR P20201815T1
Authority
HR
Croatia
Prior art keywords
nucleic acid
seq
acid molecule
treatment
pharmaceutical composition
Prior art date
Application number
HRP20201815TT
Other languages
English (en)
Croatian (hr)
Inventor
William Hearl
Teri Heiland
Original Assignee
Immunomic Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomic Therapeutics, Inc. filed Critical Immunomic Therapeutics, Inc.
Publication of HRP20201815T1 publication Critical patent/HRP20201815T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
HRP20201815TT 2012-06-15 2012-06-15 Nukleinske kiseline za liječenje alergija HRP20201815T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12878776.9A EP2861240B1 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies
PCT/US2012/042552 WO2013187906A1 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies

Publications (1)

Publication Number Publication Date
HRP20201815T1 true HRP20201815T1 (hr) 2021-02-19

Family

ID=49758576

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201815TT HRP20201815T1 (hr) 2012-06-15 2012-06-15 Nukleinske kiseline za liječenje alergija

Country Status (20)

Country Link
US (3) US9744230B2 (https=)
EP (2) EP3808361A1 (https=)
JP (1) JP5807994B2 (https=)
KR (2) KR102386481B1 (https=)
CN (2) CN107937423A (https=)
AU (3) AU2012382406B2 (https=)
BR (1) BR112014031327B1 (https=)
CA (1) CA2876824C (https=)
CY (1) CY1123769T1 (https=)
DK (1) DK2861240T3 (https=)
ES (1) ES2831723T3 (https=)
HR (1) HRP20201815T1 (https=)
HU (1) HUE052481T2 (https=)
IL (4) IL236174B (https=)
LT (1) LT2861240T (https=)
PL (1) PL2861240T3 (https=)
PT (1) PT2861240T (https=)
RS (1) RS61098B1 (https=)
SI (1) SI2861240T1 (https=)
WO (1) WO2013187906A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160185831A1 (en) * 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
AU2012382406B2 (en) * 2012-06-15 2017-12-07 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
PL2914286T3 (pl) 2012-10-30 2022-01-31 Aravax Pty Ltd Nowe cząsteczki immunoterapeutyczne oraz ich zastosowania
WO2015042664A1 (en) 2013-09-25 2015-04-02 Monash University Novel immunotherapeutic composition and uses thereof
WO2015200357A2 (en) * 2014-06-23 2015-12-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of peanut allergies
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
TWI752930B (zh) 2015-12-23 2022-01-21 德商梅迪基因免疫治療公司 抗原特異性ｔｃｒ的新生成
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
IL270024B2 (en) * 2017-04-22 2025-04-01 Immunomic Therapeutics Inc LAMP structures and their use in vaccination
KR20200016224A (ko) * 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
WO2019018529A1 (en) 2017-07-18 2019-01-24 Before Brands, Inc. METHODS OF MAKING MIXED ALLERGEN COMPOSITIONS
CN111936856A (zh) * 2018-04-06 2020-11-13 Sls生物有限公司 新型免疫球蛋白e的表位、与其结合的抗体及包括所述抗体的用于分析试料中免疫球蛋白e的试剂盒
US20210163957A1 (en) 2018-05-11 2021-06-03 Astellas Pharma Inc. Nucleic acid for treating mite allergy
JOP20200284A1 (ar) 2018-05-11 2020-11-09 Astellas Pharma Inc حمض نووي لعلاج حساسية القشريات
EP3793595A1 (en) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
AU2020213085A1 (en) 2019-01-23 2021-08-12 Société des Produits Nestlé S.A. Methods for making mixed allergen compositions
EP3938053A4 (en) * 2019-03-13 2023-03-22 Psomagen, Inc. EPITOP-BASED APPROACH TO ALLERGY TREATMENTS AND INHIBITORS FOR CROHN'S DISEASE
US12150461B2 (en) * 2021-05-04 2024-11-26 Sovida Solutions Ltd. Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
WO2023013785A1 (ja) * 2021-08-06 2023-02-09 花王株式会社 Ｓｎａｒｅを活用した核酸構築物
FI131854B1 (en) 2023-05-29 2026-01-12 Onni Biotechnologies Oy Modified natural killer cells with enhanced cytotoxic activity and greater survival

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD335810S (en) 1990-07-02 1993-05-25 Dick-Ming Asien Handle for luggage or similar article
US6982326B1 (en) 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
US6090386A (en) 1991-07-12 2000-07-18 Griffith; Irwin J. T cell peptides of the CRX JII allergen
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
CA2148713A1 (en) * 1992-11-12 1994-05-26 Mei-Chang Kuo Allergenic proteins and peptides from japanese cedar pollen
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
JP3649460B2 (ja) 1993-11-05 2005-05-18 明治乳業株式会社 スギ花粉アレルゲンＣｒｙ ｊ ＩＩエピトープ
GB9516760D0 (en) 1995-08-16 1995-10-18 Sandoz Ltd Organic compounds
EP0873135B1 (en) 1995-12-29 2009-07-22 The University of Arkansas Peanut allergens and methods
CN101307095A (zh) 1996-06-14 2008-11-19 明治乳业株式会社 T细胞表位肽
US20020142978A1 (en) * 2000-04-07 2002-10-03 Eyal Raz Synergistic improvements to polynucleotide vaccines
AU2002306850A1 (en) 2001-03-16 2002-10-03 Panacea Pharmaceuticals Methods and reagents for decreasing clinical reaction to allergy
EP1385538B1 (en) * 2001-04-05 2013-01-30 The Johns Hopkins University Chimeric Vaccines comprising the lumenal domain of LAMP-1 or LAMP-2
US20060003148A1 (en) 2004-06-30 2006-01-05 Zwynenburg James L Interlocking polymeric foam floor underlayment and process for making
WO2006099574A2 (en) 2005-03-16 2006-09-21 Tai June Yoo Cockroach allergen gene expression and delivery systems and uses
WO2006138435A2 (en) 2005-06-16 2006-12-28 Mount Sinai School Of Medicine Methods for enhancing immune responses
US7566456B2 (en) 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
JPWO2007024026A1 (ja) * 2005-08-25 2009-03-05 明石　満 Ｔ細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子
US20080006554A1 (en) 2006-07-07 2008-01-10 Medtronic Vascular, Inc. Packaging assembly for a catheter
EP2042193A1 (en) * 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
CN102186880A (zh) * 2008-09-10 2011-09-14 Ith免疫治疗控股股份公司 炎症的治疗
AU2012382406B2 (en) * 2012-06-15 2017-12-07 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
US11826423B2 (en) * 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
IL270024B2 (en) * 2017-04-22 2025-04-01 Immunomic Therapeutics Inc LAMP structures and their use in vaccination

Also Published As

Publication number Publication date
BR112014031327B1 (pt) 2022-02-01
CN107937423A (zh) 2018-04-20
AU2019250227A1 (en) 2019-11-07
JP2015521467A (ja) 2015-07-30
WO2013187906A1 (en) 2013-12-19
IL270261B (en) 2021-03-25
US9744230B2 (en) 2017-08-29
ES2831723T3 (es) 2021-06-09
DK2861240T3 (da) 2020-09-28
CA2876824C (en) 2020-07-21
IL270262A (en) 2019-12-31
RS61098B1 (sr) 2020-12-31
SI2861240T1 (sl) 2021-04-30
KR20200047792A (ko) 2020-05-07
IL236174A0 (en) 2015-01-29
CA2876824A1 (en) 2013-12-19
PL2861240T3 (pl) 2021-07-05
AU2012382406B2 (en) 2017-12-07
BR112014031327A2 (pt) 2017-06-27
PT2861240T (pt) 2020-11-09
AU2019250227B2 (en) 2021-10-21
KR102107646B1 (ko) 2020-05-08
US20220081474A1 (en) 2022-03-17
KR102386481B1 (ko) 2022-04-14
AU2012382406A2 (en) 2015-04-16
IL270260B (en) 2020-08-31
EP2861240A4 (en) 2016-03-16
JP5807994B2 (ja) 2015-11-10
EP2861240B1 (en) 2020-09-09
KR20150032286A (ko) 2015-03-25
EP3808361A1 (en) 2021-04-21
HUE052481T2 (hu) 2021-04-28
CN104519896B (zh) 2017-11-10
IL236174B (en) 2019-11-28
US20180009857A1 (en) 2018-01-11
LT2861240T (lt) 2021-01-25
AU2018200625B2 (en) 2019-09-19
CN104519896A (zh) 2015-04-15
AU2012382406A1 (en) 2014-12-18
AU2018200625A1 (en) 2018-02-15
EP2861240A1 (en) 2015-04-22
US10072053B2 (en) 2018-09-11
CY1123769T1 (el) 2022-05-27
US20160271245A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
HRP20201815T1 (hr) Nukleinske kiseline za liječenje alergija
BR112013019975A2 (pt) proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
CY1122195T1 (el) Πολυπεπτιδια συντηξης σερπινης και μεθοδοι χρησης αυτων
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
EA201200515A1 (ru) Полипептиды и их применение
BR112013032723A2 (pt) antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
EP3372617A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
EA201170635A1 (ru) Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
BR112015003947A8 (pt) Proteínas de fusão e métodos para tratar, prevenir ou melhorar dor
BR112013020338A2 (pt) proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira
CO6690759A2 (es) Anticuerpos, fragmentos de unión o derivados de los mismos que se unen específicamente a la proteína 4-1 bb
GT200500254A (es) Proceso para la concentracion de anticuerpos y productos terapeùticos relacionados.
UA107571C2 (xx) Фармацевтична композиція
AR090047A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
ECSP088262A (es) Proteínas de fusión de albúmina
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
BR112014015016A8 (pt) Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
MX358762B (es) Procesos que utilizan vlps con cápsides resistentes a hidrolasas.
CO6210831A2 (es) Nuevas proteinas h5 moleculas de acido nucleico y vectores que las codifican y su uso medicinal
BR112014018884A2 (pt) antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b
EP2672992A4 (en) FOR A HEPATITIS B-VIRUS CORE PROTEIN, CODING NUCLEIC ACID MOLECULE AND VACCINE WITH IT
RU2015126105A (ru) Модифицированные суперспиральные белки с улучшенными свойствами
US20160362454A1 (en) Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
AR069584A1 (es) Proteinas de elastasa recombinantes y sus metodos de preparacion y su uso